Selected research
Market Structure
Global Cancer Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cancer Pain market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cancer Pain include Teva pharmaceuticals, Sanofi, Johnson＆Johnson, Eli-Lilly, WEX Pharmaceuticals, ProStrakan Group, Orexo, Meda Pharmaceuticals and GW Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Cancer Pain market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cancer Pain and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cancer Pain revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Cancer Pain market size, projected growth trends, production technologies, key applications, and end-use industries.
Cancer Pain Segment by Company
Teva pharmaceuticals
Sanofi
Johnson＆Johnson
Eli-Lilly
WEX Pharmaceuticals
ProStrakan Group
Orexo
Meda Pharmaceuticals
GW Pharmaceuticals
Grunenthal Group
BioDelivery Science
Cancer Pain Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Cancer Pain Segment by Application
Hormone Therapy
Chemotherapy
Radiotherapy
Others
Cancer Pain Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Cancer Pain in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Pain industry.
Chapter 3: Detailed analysis of Cancer Pain companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Painrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Opioids
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Applications
- Hormone Therapy
- Chemotherapy
- Radiotherapy
- Others
Companies covered
- Teva pharmaceuticals
- Sanofi
- Johnson＆Johnson
- Eli-Lilly
- WEX Pharmaceuticals
- ProStrakan Group
- Orexo
- Meda Pharmaceuticals
- GW Pharmaceuticals
- Grunenthal Group
- BioDelivery Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Cancer Pain Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Opioids
- 1.2.3 Non-Steroidal Anti-Inflammatory Drugs
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Cancer Pain Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hormone Therapy
- 1.3.3 Chemotherapy
- 1.3.4 Radiotherapy
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Cancer Pain Growth Trends by Region
- 1.5.1 Global Cancer Pain Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Cancer Pain Market Size by Region (2021-2026)
- 1.5.3 Cancer Pain Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Cancer Pain Market Dynamics
- 2.1 Cancer Pain Industry Trends
- 2.2 Cancer Pain Industry Drivers
- 2.3 Cancer Pain Industry Opportunities and Challenges
- 2.4 Cancer Pain Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Cancer Pain Revenue by Company (2021-2026)
- 3.2 Global Cancer Pain Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Cancer Pain Key Company Head office and Area Served
- 3.4 Global Cancer Pain Company, Product Type & Application
- 3.5 Global Cancer Pain Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Cancer Pain Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Cancer Pain Players Market Share by Revenue in 2025
- 3.6.3 2025 Cancer Pain Tier 1, Tier 2, and Tier 3
4 Cancer Pain Market by Type
- 4.1 Global Cancer Pain Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Cancer Pain Market Size by Type (2021-2032)
- 4.3 Global Cancer Pain Market Size Share by Type (2021-2032)
5 Cancer Pain Market by Application
- 5.1 Global Cancer Pain Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Cancer Pain Market Size by Application (2021-2032)
- 5.3 Global Cancer Pain Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Teva pharmaceuticals
- 6.1.1 Teva pharmaceuticals Company Information
- 6.1.2 Teva pharmaceuticals Business Overview
- 6.1.3 Teva pharmaceuticals Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Teva pharmaceuticals Cancer Pain Product Portfolio
- 6.1.5 Teva pharmaceuticals Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sanofi Cancer Pain Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Johnson＆Johnson
- 6.3.1 Johnson＆Johnson Company Information
- 6.3.2 Johnson＆Johnson Business Overview
- 6.3.3 Johnson＆Johnson Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Johnson＆Johnson Cancer Pain Product Portfolio
- 6.3.5 Johnson＆Johnson Recent Developments
- 6.4 Eli-Lilly
- 6.4.1 Eli-Lilly Company Information
- 6.4.2 Eli-Lilly Business Overview
- 6.4.3 Eli-Lilly Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Eli-Lilly Cancer Pain Product Portfolio
- 6.4.5 Eli-Lilly Recent Developments
- 6.5 WEX Pharmaceuticals
- 6.5.1 WEX Pharmaceuticals Company Information
- 6.5.2 WEX Pharmaceuticals Business Overview
- 6.5.3 WEX Pharmaceuticals Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 WEX Pharmaceuticals Cancer Pain Product Portfolio
- 6.5.5 WEX Pharmaceuticals Recent Developments
- 6.6 ProStrakan Group
- 6.6.1 ProStrakan Group Company Information
- 6.6.2 ProStrakan Group Business Overview
- 6.6.3 ProStrakan Group Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 ProStrakan Group Cancer Pain Product Portfolio
- 6.6.5 ProStrakan Group Recent Developments
- 6.7 Orexo
- 6.7.1 Orexo Company Information
- 6.7.2 Orexo Business Overview
- 6.7.3 Orexo Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Orexo Cancer Pain Product Portfolio
- 6.7.5 Orexo Recent Developments
- 6.8 Meda Pharmaceuticals
- 6.8.1 Meda Pharmaceuticals Company Information
- 6.8.2 Meda Pharmaceuticals Business Overview
- 6.8.3 Meda Pharmaceuticals Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Meda Pharmaceuticals Cancer Pain Product Portfolio
- 6.8.5 Meda Pharmaceuticals Recent Developments
- 6.9 GW Pharmaceuticals
- 6.9.1 GW Pharmaceuticals Company Information
- 6.9.2 GW Pharmaceuticals Business Overview
- 6.9.3 GW Pharmaceuticals Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 GW Pharmaceuticals Cancer Pain Product Portfolio
- 6.9.5 GW Pharmaceuticals Recent Developments
- 6.10 Grunenthal Group
- 6.10.1 Grunenthal Group Company Information
- 6.10.2 Grunenthal Group Business Overview
- 6.10.3 Grunenthal Group Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Grunenthal Group Cancer Pain Product Portfolio
- 6.10.5 Grunenthal Group Recent Developments
- 6.11 BioDelivery Science
- 6.11.1 BioDelivery Science Company Information
- 6.11.2 BioDelivery Science Business Overview
- 6.11.3 BioDelivery Science Cancer Pain Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 BioDelivery Science Cancer Pain Product Portfolio
- 6.11.5 BioDelivery Science Recent Developments
7 North America
- 7.1 North America Cancer Pain Market Size (2021-2032)
- 7.2 North America Cancer Pain Market Size by Type
- 7.2.1 North America Cancer Pain Market Size by Type (2021-2026)
- 7.2.2 North America Cancer Pain Market Size by Type (2027-2032)
- 7.2.3 North America Cancer Pain Market Share by Type (2021-2032)
- 7.3 North America Cancer Pain Market Size by Application
- 7.3.1 North America Cancer Pain Market Size by Application (2021-2026)
- 7.3.2 North America Cancer Pain Market Size by Application (2027-2032)
- 7.3.3 North America Cancer Pain Market Share by Application (2021-2032)
- 7.4 North America Cancer Pain Market Size by Country
- 7.4.1 North America Cancer Pain Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Cancer Pain Market Size by Country (2021-2026)
- 7.4.3 North America Cancer Pain Market Size by Country (2027-2032)
- 7.4.4 North America Cancer Pain Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Cancer Pain Market Size (2021-2032)
- 8.2 Europe Cancer Pain Market Size by Type
- 8.2.1 Europe Cancer Pain Market Size by Type (2021-2026)
- 8.2.2 Europe Cancer Pain Market Size by Type (2027-2032)
- 8.2.3 Europe Cancer Pain Market Share by Type (2021-2032)
- 8.3 Europe Cancer Pain Market Size by Application
- 8.3.1 Europe Cancer Pain Market Size by Application (2021-2026)
- 8.3.2 Europe Cancer Pain Market Size by Application (2027-2032)
- 8.3.3 Europe Cancer Pain Market Share by Application (2021-2032)
- 8.4 Europe Cancer Pain Market Size by Country
- 8.4.1 Europe Cancer Pain Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Cancer Pain Market Size by Country (2021-2026)
- 8.4.3 Europe Cancer Pain Market Size by Country (2027-2032)
- 8.4.4 Europe Cancer Pain Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Cancer Pain Market Size (2021-2032)
- 9.2 China Cancer Pain Market Size by Type
- 9.2.1 China Cancer Pain Market Size by Type (2021-2026)
- 9.2.2 China Cancer Pain Market Size by Type (2027-2032)
- 9.2.3 China Cancer Pain Market Share by Type (2021-2032)
- 9.3 China Cancer Pain Market Size by Application
- 9.3.1 China Cancer Pain Market Size by Application (2021-2026)
- 9.3.2 China Cancer Pain Market Size by Application (2027-2032)
- 9.3.3 China Cancer Pain Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Cancer Pain Market Size (2021-2032)
- 10.2 Asia Cancer Pain Market Size by Type
- 10.2.1 Asia Cancer Pain Market Size by Type (2021-2026)
- 10.2.2 Asia Cancer Pain Market Size by Type (2027-2032)
- 10.2.3 Asia Cancer Pain Market Share by Type (2021-2032)
- 10.3 Asia Cancer Pain Market Size by Application
- 10.3.1 Asia Cancer Pain Market Size by Application (2021-2026)
- 10.3.2 Asia Cancer Pain Market Size by Application (2027-2032)
- 10.3.3 Asia Cancer Pain Market Share by Application (2021-2032)
- 10.4 Asia Cancer Pain Market Size by Country
- 10.4.1 Asia Cancer Pain Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Cancer Pain Market Size by Country (2021-2026)
- 10.4.3 Asia Cancer Pain Market Size by Country (2027-2032)
- 10.4.4 Asia Cancer Pain Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Cancer Pain Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Cancer Pain Market Size by Type
- 11.2.1 South America, Middle East & Africa Cancer Pain Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Cancer Pain Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Cancer Pain Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Cancer Pain Market Size by Application
- 11.3.1 South America, Middle East & Africa Cancer Pain Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Cancer Pain Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Cancer Pain Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Cancer Pain Market Size by Country
- 11.4.1 South America, Middle East & Africa Cancer Pain Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Cancer Pain Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Cancer Pain Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Cancer Pain Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst